Vientiane,Laos PDR, July 24, 2022 /LienTeh/
Yesterday，World Health Organization（WHO） declares fast spreading monkeypox outbreak a global health emergency.［1］
Several pharmaceutical companies that reached the plan through the ALBA TEAM mechanism urgently convened relevant responsible persons for a brief discussion on Sunday, and decided to start the development of the manufacturing formula and technological process of antiviral drugs.
According to the participants who did not want to be named, the drugs currently included in the development plan of several pharmaceutical companies in Laos include: Tecovirimat & Brincidofovir.
And the members of the meeting unanimously agreed to file a manufacturing license for the drug with the Lao regulatory authorities at an appropriate time in the future.
Monkeypox virus is an enveloped double-stranded DNA virus that belongs to the Orthopoxvirus genus of the Poxviridae family. There are two distinct genetic clades of the monkeypox virus – the Central African (Congo Basin) clade and the West African clade. The Congo Basin clade has historically caused more severe disease and was thought to be more transmissible. The geographical division between the two clades has so far been in Cameroon - the only country where both virus clades have been found.
Tecovirimat is an antiviral medication with activity against orthopoxviruses such as smallpox and monkeypox. It is the first antipoxviral drug approved in the United States.The drug works by blocking cellular transmission of the virus, thus preventing the disease. Tecovirimat has been effective in laboratory testing; it has been shown to protect animals from monkeypox and rabbitpox and causes no serious side effects in humans.Two million doses of tecovirimat are stockpiled in the US Strategic National Stockpile should an orthopoxvirus-based bioterror attack occur.The U.S. Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Brincidofovir is an orally bioavailable lipid acyclic nucleotide phosphonate. Upon metabolism, brincidofovir yields high intracellular levels of cidofovir diphosphate and exhibits enhanced in vitro antiviral activity against a wide range of double-stranded DNA viruses, including herpesviruses. Brincidofovir is delivered into target cells whereupon the lipid side chain is cleaved, releasing cidofovir to be further phosphorylated by intracellular kinases to cidofovir diphosphate. Cidofovir diphosphate acts as inhibitor of DNA Pol, resulting in decreased DNA synthesis and chain termination.
Brincidofovir is under investigation for the treatment of cytomegalovirus, adenovirus, poxvirus, and ebolavirus infections. It has been used off-label for the treatment of monkeypox. 
ALBA TEAM is the system of persons acting in concert.It is a rapid response mechanism established to meet the challenges of public health crisis, major diseases and rare diseases.We hope that the cooperation among members can meet the outstanding medical needs.
RxLibra Pharmaceutical is a pharmaceutical industry service provider,It is THIRD PARTY PHARMA SERVICES focusing on Consulting services&Formulation manufacturing&Medicine exports.
DAXIONMG Pharmaceutical founded in 2020, it was established in Laos. Focusing on the research and development of generic drugs, focusing on the future. Daxiong Pharmaceutical stands on the shoulders of giants and is committed to achieving consistency with the original research in all aspects. Love Life Better Tommorow. Love life, beautiful tomorrow. Daxiong Pharmaceuticals.
Sailin biopharmaceutical (Laos) co., LTD., and the construction in 2019, is currently the largest and the most technologically advanced Laos anticancer and antiviral drugs production enterprise joint pharmaceutical group co., LTD., a subsidiary of the country's fastest growing large pharmaceutical companies.
BioSpring(laos) group Co.,LTD, established in 2022, Adhering to the concept of "Healing Beyond Boundaries", focusing on human and veterinary medicines, the goal is to become a leader in the pharmaceutical industry in Laos.